Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 8/2017

01-08-2017 | Original Article

Radioablation of adrenal gland malignomas with interstitial high-dose-rate brachytherapy

Efficacy and outcome

Authors: K. Mohnike, K. Neumann, P. Hass, M. Seidensticker, R. Seidensticker, M. Pech, S. Klose, T. Streitparth, B. Garlipp, C. Benckert, J. J. Wendler, U. B. Liehr, M. Schostak, D. Göppner, G. Gademann, J. Ricke

Published in: Strahlentherapie und Onkologie | Issue 8/2017

Login to get access

Abstract

Purpose

To assess the efficacy, safety, and outcome of image-guided high-dose-rate (HDR) brachytherapy in patients with adrenal gland metastases (AGM).

Materials and methods

From January 2007 to April 2014, 37 patients (7 female, 30 male; mean age 66.8 years, range 41.5–82.5 years) with AGM from different primary tumors were treated with CT-guided HDR interstitial brachytherapy (iBT). Primary endpoint was local tumor control (LTC). Secondary endpoints were time to untreatable progression (TTUP), time to progression (TTP), overall survival (OS), and safety. In a secondary analysis, risk factors with an influence on survival were identified.

Results

The median biological equivalent dose (BED) was 37.4 Gy. Mean LTC after 12 months was 88%; after 24 months this was 74%. According to CTCAE criteria, one grade 3 adverse event occurred. Median OS after first diagnosis of AGM was 18.3 months. Median OS, TTUP, and TTP after iBT treatment were 11.4, 6.6, and 3.5 months, respectively. Uni- and multivariate Cox regression analyses revealed significant influences of synchronous disease, tumor diameter, and the total number of lesions on OS or TTUP or both.

Conclusion

Image-guided HDR-iBT is safe and effective. Treatment- and primary tumor-independent features influenced survival of patients with AGM after HDR-iBR treatment.
Literature
1.
2.
Sterzing F, Brunner TB, Ernst I et al (2014) Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 190:872–881CrossRefPubMed
3.
Glomset DA (1938) The incidence of metastasis of malignant tumors to the adrenals. Am J Cancer 32:57–61CrossRef
4.
Lenert JT, Barnett CC Jr., Kudelka AP et al (2001) Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy. Surgery 130:1060–1067CrossRefPubMed
5.
Milano MT, Katz AW, Muhs AG et al (2008) A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 112:650–658CrossRefPubMed
6.
Twomey P, Montgomery C, Clark O (1982) Successful treatment of adrenal metastases from large-cell carcinoma of the lung. JAMA 248:581–583CrossRefPubMed
7.
Ahmed KA, Barney BM, Macdonald OK et al (2013) Stereotactic body radiotherapy in the treatment of adrenal metastases. Am J Clin Oncol 36:509–513CrossRefPubMed
8.
Holy R, Piroth M, Pinkawa M, Eble MJ (2011) Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 187:245–251CrossRefPubMed
9.
Rudra S, Malik R, Ranck MC et al (2013) Stereotactic body radiation therapy for curative treatment of adrenal metastases. Technol Cancer Res Treat 12:217–224CrossRefPubMed
10.
Scorsetti M, Alongi F, Filippi AR et al (2012) Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol (Madr) 51:618–623CrossRef
11.
Torok J, Wegner RE, Burton SA, Heron DE (2011) Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. Future Oncol 7:145–151CrossRefPubMed
12.
Carrafiello G, Lagana D, Recaldini C et al (2008) Imaging-guided percutaneous radiofrequency ablation of adrenal metastases: preliminary results at a single institution with a single device. Cardiovasc Intervent Radiol 31:762–767CrossRefPubMed
13.
Haga H, Saito T, Okumoto K et al (2005) Successful percutaneous radiofrequency ablation of adrenal metastasis from hepatocellular carcinoma. J Gastroenterol 40:1075–1076CrossRefPubMed
14.
Kuehl H, Stattaus J, Forsting M, Antoch G (2008) Transhepatic CT-guided radiofrequency ablation of adrenal metastases from hepatocellular carcinoma. Cardiovasc Intervent Radiol 31:1210–1214CrossRefPubMed
15.
Lo WK, van Sonnenberg E, Shankar S et al (2006) Percutaneous CT-guided radiofrequency ablation of symptomatic bilateral adrenal metastases in a single session. J Vasc Interv Radiol 17:175–179CrossRefPubMed
16.
Wood BJ, Abraham J, Hvizda JL, Alexander HR, Fojo T (2003) Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 97:554–560CrossRefPubMedPubMedCentral
17.
Yamakado K, Anai H, Takaki H et al (2009) Adrenal metastasis from hepatocellular carcinoma: radiofrequency ablation combined with adrenal arterial chemoembolization in six patients. Am J Roentgenol 192:W300–5CrossRef
18.
Wang Y, Liang P, Yu X, Cheng Z, Yu J, Dong J (2009) Ultrasound-guided percutaneous microwave ablation of adrenal metastasis: preliminary results. Int J Hyperthermia 25:455–461CrossRefPubMed
19.
Gunjur A, Duong C, Ball D, Siva S (2014) Surgical and ablative therapies for the management of adrenal ‘oligometastases’ – a systematic review. Cancer Treat Rev 40:838–846CrossRefPubMed
20.
Ricke J, Wust P, Wieners G et al (2004) Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol 15:1279–1286CrossRefPubMed
21.
Ricke J, Wust P, Wieners G et al (2005) CT-guided interstitial single-fraction brachytherapy of lung tumors: phase I results of a novel technique. Chest 127:2237–2242CrossRefPubMed
22.
Collettini F, Schippers AC, Schnapauff D et al (2013) Percutaneous ablation of lymph node metastases using CT-guided high-dose-rate brachytherapy. Br J Radiol 86:20130088CrossRefPubMedPubMedCentral
23.
Mohnike K, Wieners G, Schwartz F et al (2010) Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 78:172–179CrossRefPubMed
24.
Peters N, Wieners G, Pech M et al (2008) CT-guided interstitial brachytherapy of primary and secondary lung malignancies: results of a prospective phase II trial. Strahlenther Onkol 184:296–301CrossRefPubMed
25.
Ricke J, Mohnike K, Pech M et al (2010) Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 78:479–485CrossRefPubMed
26.
Collettini F, Schreiber N, Schnapauff D et al (2015) CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma. Strahlenther Onkol 191:405–412CrossRefPubMed
27.
Kishi K, Tamura S, Mabuchi Y et al (2012) Percutaneous interstitial brachytherapy for adrenal metastasis: technical report. J Radiat Res 53:807–814CrossRefPubMedPubMedCentral
28.
Wieners G, Pech M, Rudzinska M et al (2006) CT-guided interstitial brachytherapy in the local treatment of extrahepatic, extrapulmonary secondary malignancies. Eur Radiol 16:2586–2593CrossRefPubMed
29.
Lopez Guerra JL, Gomez D, Zhuang Y et al (2012) Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys 84:e61–e67CrossRefPubMed
30.
Dawson LA (2011) Overview: where does radiation therapy fit in the spectrum of liver cancer local-regional therapies? Semin Radiat Oncol 21:241–246CrossRefPubMed
31.
Thomas TO, Hasan S, Small W Jr. et al (2014) The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far? J Gastrointest Oncol 5:236–246PubMedPubMedCentral
32.
Mohnike K, Wolf S, Damm R et al (2016) Radioablation of liver malignancies with interstitial high-dose-rate brachytherapy: complications and risk factors. Strahlenther Onkol 192:288–296CrossRefPubMed
33.
Oshiro Y, Takeda Y, Hirano S, Ito H, Aruga T (2011) Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. Am J Clin Oncol 34:249–253CrossRefPubMed
Metadata
Title
Radioablation of adrenal gland malignomas with interstitial high-dose-rate brachytherapy
Efficacy and outcome
Authors
K. Mohnike
K. Neumann
P. Hass
M. Seidensticker
R. Seidensticker
M. Pech
S. Klose
T. Streitparth
B. Garlipp
C. Benckert
J. J. Wendler
U. B. Liehr
M. Schostak
D. Göppner
G. Gademann
J. Ricke
Publication date
01-08-2017
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 8/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1120-2

Other articles of this Issue 8/2017

Strahlentherapie und Onkologie 8/2017 Go to the issue

Original Article

Automation of radiation treatment planning

Case Study

Successful treatment of a rare case of ameloblastic fibrosarcoma with radiation therapy

Original Article

Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients

Original Article

Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer

Erratum

Erratum to: Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters

Literatur kommentiert

30-Tage-Letalität nach systemischer Chemotherapie